Sickle Cell Anemia



A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)


Condition:   Sickle Cell Disease
Intervention:   Drug: IMR-687
Sponsor:   Imara, Inc.
Recruiting


Risk Factors for Allo-immunization in Sickle Cell Disease


Condition:   Sickle Cell Disease
Intervention:   Other: Medical file data collection
Sponsor:   Hanane EL KENZ
Not yet recruiting


Implication of the Oxydative Stress in the Pathophysiology of Sickle Cell Anemia:


Condition:   Sickle Cell Disease
Intervention:   Other: SCA patients (SS genotype)
Sponsor:   Centre Hospitalier Universitaire de Pointe-a-Pitre
Completed


Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Ilaris, Canakinumab;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting


SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Hydroxyurea;   Procedure: TCD examination
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Hospital Infantil Dr. Robert Reid Cabral
Recruiting


The Role of Endothelin-1 in Sickle Cell Disease


Condition:   Sickle Cell Anemia
Interventions:   Drug: Ambrisentan;   Drug: Placebo
Sponsors:   Augusta University;   Gilead Sciences;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting


SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge


Condition:   Sickle Cell Disease
Intervention:   Device: SMART app
Sponsor:   Duke University
Recruiting


Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease


Condition:   Sickle Cell Anemia
Intervention:  
Sponsor:   Albert Einstein College of Medicine, Inc.
Active, not recruiting


Gene Transfer for Patients With Sickle Cell Disease


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Intervention:   Genetic: Gene transfer
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Doris Duke Charitable Foundation
Recruiting


Study of Beet Juice for Patients With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Intervention:   Drug: beet juice (Unbeetable)
Sponsors:   Wake Forest University Health Sciences;   Wake Forest University;   National Heart, Lung, and Blood Institute (NHLBI)
Suspended


Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Intervention:   Drug: hydroxyurea
Sponsors:   Loyola University;   University of Illinois at Chicago;   University of Ibadan
Active, not recruiting


Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study


Condition:   Sickle Cell Anemia
Interventions:   Drug: Hydroxyurea;   Other: Placebo
Sponsor:   Children's Research Institute
Withdrawn


Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia


Condition:   Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions:   Drug: Montelukast added to Hydroxyurea;   Drug: Placebo added to Hydroxyurea
Sponsors:   Vanderbilt University Medical Center;   Medical College of Wisconsin;   Blood Center of Wisconsin
Recruiting


Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study


Conditions:   Sickle Cell Anemia;   Sickle Cell β+ or β0 Thalassemia
Intervention:  
Sponsor:   HaEmek Medical Center, Israel
Recruiting


Stem Cell Transplantation for Sickle Cell Anemia


Condition:   Sickle Cell Disease
Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Procedure: Stem Cells
Sponsor:   Hackensack University Medical Center
Recruiting


A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Intervention:   Drug: N-Acetylcysteine
Sponsors:   Bloodworks (Puget Sound Blood Center);   University of Washington
Enrolling by invitation


Microvascular Blood Flow in Sickle Cell Anemia


Conditions:   Sickle Cell Disease;   Sickle Cell Anemia
Interventions:   Drug: regadenoson infusion with contrast-enhanced ultrasound;   Procedure: contrast-enhanced ultrasound
Sponsors:   Blood Center of Wisconsin;   Medical College of Wisconsin;   La Jolla Institute for Allergy & Immunology;   University of Illinois at Chicago;   Oregon Health and Science University;   Dana-Farber Cancer Institute
Active, not recruiting


Iron Mediated Vascular Disease in Sickle Cell Anemia Patients


Condition:   Sickle Cell Disease
Intervention:  
Sponsor:   Children's Hospital Los Angeles
Active, not recruiting


A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia


Conditions:   Sickle Cell Anemia;   Sickle ß0-Thalassemia
Interventions:   Drug: L-glutamine;   Drug: Placebo
Sponsor:   Emmaus Medical, Inc.
Completed


Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders


Condition:   Sickle Cell Disease
Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting


L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia


Conditions:   Sickle Cell Anemia;   Thalassemia
Interventions:   Drug: L-glutamine;   Drug: Placebo
Sponsors:   Emmaus Medical, Inc.;   FDA Office of Orphan Products Development
Completed


Heart Disease in Sickle Cell Anemia


Conditions:   Sickle Cell Anemia;   Pulmonary Hypertension
Intervention:  
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed


Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease


Condition:   Sickle Cell Anemia
Interventions:   Drug: L-NMMA;   Drug: Sodium Nitrite
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed


Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Interventions:   Drug: Hydroxyurea;   Drug: L-Arginine;   Drug: Sildenafil
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed


Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia


Condition:   Sickle Cell Anemia
Intervention:   Drug: Hydroxyurea
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed

Refine Your Search Advanced Search